AbbVie: Comeback Expected After Humira Patent Expiration

vzphotos There’s no sugarcoating the fact that AbbVie (NYSE:ABBV), the biggest healthcare stock by market capitalisation after Eli Lilly and Company (LLY), has seen dismal full-year results for 2023 last month with a 6.4% decline in revenue and a huge 59% drop in reported earnings per share [EPS]. Still, its price is on the up and up. Year-to-date [YTD], its price has risen by over 15%. To contextualise, the S&P 500 Health Care Index is up by less than half this at 7.1%. With this disconnect between fun ...